-
April 10, 2023 Study Shares Promising Data that DMT May Treat Major Depressive DisorderPhase IIa clinical trial exploring the use of DMT for Major Depressive Disorder has revealed...
-
March 10, 2023 The Biggest Psychedelic News Stories This Week – March 10Health Canada's decision to deny a terminally ill Saskatoon man permission to continue psychedelic psilocybin...
-
February 24, 2023 The Biggest Psychedelic News Stories This Week – February 24This week witnessed a wave of US states dwelling on psychedelic policies to be included...
-
July 22, 2022 A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 TrialCompass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new...
-
May 27, 2022 5 Next-Generation Psychedelics Entering Clinical Trials This YearModernized psychedelic medicine is coming, whether you like it or not, so here are five...
-
March 30, 2022 5 Most Important Psychedelic Clinical Trials in 2022Here's why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic...
-
March 18, 2022 Is Small Pharma a Good Psychedelic Stock Investment?Our resident Psychedelic Investor James Hallifax looks at the pros and cons of this Canadian-based...
-
March 11, 2022 Psychedelic Business Spotlight- March 11This week in psychedelic business news: Small Pharma prepares big DMT studies; Health Canada approves...
-
October 22, 2021 Psychedelic Business Spotlight: October 22This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field...
-
September 24, 2021 Psychedelic Business Spotlight: September 24, 2021This week in psychedelic business news: two patents may revolutionize the medical application of psychedelic...
